关于含有pyrrolidone单位的多孔微球的合成和特征的观点
1Department of Polymer Chemistry, Institute of Chemical Sciences, Faculty of Chemistry, Maria Curie-Skłodowska University in Lublin, Gliniana 33, 20-614 Lublin, Poland.
研究人员为分离技术的应用合成了带有罗利子子单位的多孔聚合物球体. 这些材料表现出高表面积和良好的热稳定性,使它们适合气相色谱静止相.
科学领域:
- 聚合物化学 聚合物化学
- 材料科学 材料科学 材料科学
- 分离科学 分离科学
背景情况:
- 多孔材料对于分离技术,催化和染色学至关重要.
- 多孔聚合物的合成涉及各种单体和聚合技术.
- 含罗利的聚合物为先进的应用提供了独特的特性.
研究的目的:
- 合成和表征交联的多孔聚合物球体,其中包括pyrrolidone子单元.
- 研究不同合成参数对材料性能的影响.
- 评估这些聚合物作为气体染色学中静止相的潜力.
主要方法:
- 直接合成N-乙烯基-2-pyrrolidone (NVP) 和乙烯基甘醇二甲酸盐 (EGDMA) 的共聚物.
- 修改多孔的poly ((glycidyl甲基酸盐-co-乙烯基醇二甲基酸盐) 用皮罗利.
- 使用形成孔隙的稀释剂 (托卢,多德,多德-1-ol) 来控制孔隙性.
- 通过尺寸分布,ATR-FTIR,SEM,TGA,逆气色谱和吸附/脱附进行表征.
主要成果:
- 合成的多孔聚合物 (VP-co-EGDMA) kopo 聚合物,其特定表面积在 55-468 m2/g 之间.
- 鉴定证实了多孔结构和pyrrolidone子单元的结合.
- 优化合成参数导致具有可调节的多孔性和表面性质的材料.
结论:
- 合成的含有罗利的多孔聚合物显示出出色的热稳定性.
- 这些材料是气体染色学中静止相的有希望的候选材料.
- 该研究为制造用于分离应用的功能性多孔聚合物提供了可行的途径.
更多相关视频
08:53Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery
Published on: April 16, 2019
14:11Synthesis of pH Dependent Pyrazole, Imidazole, and Isoindolone Dipyrrinone Fluorophores using a Claisen-Schmidt Condensation Approach
Published on: June 10, 2021
相关概念视频
Five-Membered Heterocyclic Aromatic Compounds: Overview
Basicity of Heterocyclic Aromatic Amines
Pore Transport and Ion-Pair Transport
Pore transport, also known as convective transport, is a process where small molecules like urea, water, and sugars rapidly cross cell membranes as though there were channels or pores in the membrane. Although direct microscopic evidence is limited but the concept of pores or channels is widely accepted based on physiological evidence. Despite the lack of direct microscopic...
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
